Highbridge Capital Management’s Bellevue Life Sciences Acquisition Corp. Rights BLACR Stock Holding History

Highbridge Capital Management’s Portfolio BLACR Stock Details BLACR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-836,469	Closed	-$100K	–	314
2024 Q4	$100K	Hold	836,469	–	–	﹤0.01%	204
2024 Q3	$87.2K	Hold	836,469	–	–	﹤0.01%	206
2024 Q2	$92.9K	Hold	836,469	–	–	﹤0.01%	193
2024 Q1	$125K	Hold	836,469	–	–	﹤0.01%	170
2023 Q4	$125K	Buy	836,469 +100,000	+14%	+$16.2K	0.01%	156
2023 Q3	$206K	Hold	736,469	–	–	0.01%	179
2023 Q2	$169K	Buy	736,469 +160,000	+28%	+$27.9K	0.01%	188
2023 Q1	$104K	Buy	+576,469	New	+$89.6K	﹤0.01%	249

Highbridge Capital Management's BLACR Position: Q1 2025 in Review

Highbridge Capital Management sold out of Bellevue Life Sciences Acquisition Corp. Rights (BLACR) in Q1 2025, closing a stake of 836,469 shares — an estimated $100K sold.

Highbridge Capital Management first reported a position in BLACR in Q1 2023 and held it in 8 quarters. The position peaked at $206K in Q3 2023. 0 funds tracked by Wall St. Rank hold BLACR as of Q1 2025.

Highbridge Capital Management reported no remaining Bellevue Life Sciences Acquisition Corp. Rights position as of Q1 2025 after selling out during the quarter.
Highbridge Capital Management sold 836,469 Bellevue Life Sciences Acquisition Corp. Rights shares in Q1 2025, an estimated $100K.
Highbridge Capital Management first reported a position in Bellevue Life Sciences Acquisition Corp. Rights in Q1 2023 and held it in 8 quarters.
Highbridge Capital Management's Bellevue Life Sciences Acquisition Corp. Rights position peaked at $206K in Q3 2023.
0 funds tracked by Wall St. Rank held Bellevue Life Sciences Acquisition Corp. Rights as of Q1 2025.

Based on Highbridge Capital Management's 13F filing for Q1 2025, filed 12 May 2025.